Evidence from multiple ongoing clinical trials proves that genome editing can attain robust disease-modifying outcomes in multiple indications including sickle cell disease, transfusion-dependent beta-thalassemia, and TTR amyloidosis. Current regulatory and manufacturing frameworks, however, are not scaled to expand the clinical footprint of CRISPR to a substantial fraction of Mendelian disease, even in settings where a charted path exists to advance editing to the clinic (such as inborn errors of immunity). Such an expansion will require the engineering and clinical development of a fundamentally new approach to designing, developing, and deploying CRISPR-based genomic medicines. The academic/nonprofit sector is a key venue for this effort, with nonmalignant hematology as an actionable disease space for reducing such an approach to practice in the next 3-5 years.
The European Laboratory Research & Innovation Group
Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Get the App
Get this event information on your mobile by going to the Apple or Google Store and search for 'myEventflo'